Brookfield Asset Management Inc. is exploring a sale of its life-sciences real estate portfolio, and seeking about $3 billion, according to people with knowledge of the matter.
The Toronto-based alternative asset manager is working with advisers to sell roughly 2.3 million square feet of life-sciences real estate it acquired as part of its 2018 purchase of Forest City Realty Trust Inc., said the people, who requested anonymity because the information isn’t public.
A Brookfield representative declined to comment.
Blackstone Group Inc. agreed last week to recapitalize a portfolio of BioMed Realty life-sciences buildings for $14.6 billion, a deal that will generate $6.5 billion of cumulative profits four years after investing in the properties.
Life sciences, which includes pharmaceutical, biotech and other medical research fields, is a sector where most staff can’t work remotely. That has stabilized the value of such properties.
Alexandria Real Estate Equities Inc., one of the largest real estate investment trusts that owns on life sciences properties, has fallen 2% this year compared to a 14.6% decline of the Bloomberg U.S. REITs Index.
Source: Bloomberg
Can’t stop reading? Read more
Apollo raises $35bn through Asia expansion
Alternative asset management major Apollo Global Management has raised $35bn from Asian investors...
Apollo to help finance Concord’s $1.4bn Hipgnosis Songs Fund acquisition
Apollo Global Management has agreed to help finance the acquisition of British song investor...
Ardian SAS to Acquire $1bn in Private Equity Stakes
Ardian set to acquire over $1 billion of BCI's private equity stakes amid market shifts and high...